Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin

Affiliation auteurs!!!! Error affiliation !!!!
TitreAnalysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin
Type de publicationJournal Article
Year of Publication2019
AuteursHeld G, Haioun C, Houot R, Gaulard P, Molina T, Rosenwald A, Andre M, Hoffmann J, Dreyling M, Casasnovas O, Maisonneuve H, Tilly H, Illmer T, Mayer S, Kirchen H, La Rosee P, Loeffler M, Ziepert M, Altmann B, Poeschel V
JournalBLOOD
Volume134
Date PublishedNOV 13
Type of ArticleMeeting Abstract
ISSN0006-4971
DOI10.1182/blood-2019-129347